SEC Form 4 · accession 0001144204-15-071586
INTERCEPT PHARMACEUTICALS, INC. · ICPT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David Shapiro
Officer — CMO and EVP - Development
Period of report
Dec 15, 2015
Accepted (ET)
Dec 17, 2015 · 9:00 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001270073
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Dec 15, 2015 | M | 3,500 | $8.6667 | A | 31,895 | D | |
| Common Stock | Dec 15, 2015 | S | 2,500 | $157.3801 | D | 29,395 | D | |
| Common Stock | Dec 15, 2015 | S | 1,000 | $157.45 | D | 28,395 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to Purchase Common StockF2 | $8.6667 | Dec 15, 2015 | M | 3,500 | D | — | Aug 16, 2020 | Common Stock | 3,500 | 0 | D |
Explanation of responses
- F1The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on November 25, 2014.
- F2All shares underlying this option have vested.